-
Je něco špatně v tomto záznamu ?
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update
M. Rouprêt, T. Seisen, AJ. Birtle, O. Capoun, EM. Compérat, JL. Dominguez-Escrig, I. Gürses Andersson, F. Liedberg, P. Mariappan, A. Hugh Mostafid, B. Pradere, BWG. van Rhijn, SF. Shariat, BP. Rai, F. Soria, V. Soukup, RG. Wood, EN. Xylinas, A....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
- MeSH
- karcinom z přechodných buněk * diagnóza terapie patologie MeSH
- ledvinná pánvička patologie MeSH
- lidé MeSH
- nádory ledvin * diagnóza terapie patologie MeSH
- nádory močového měchýře * patologie MeSH
- nádory močovodu * diagnóza terapie patologie MeSH
- urologie * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
CONTEXT: The European Association of Urology (EAU) guidelines panel on upper urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in evidence-based management of UTUC. OBJECTIVE: To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. EVIDENCE ACQUISITION: The recommendations provided in these guidelines are based on a review of the literature via a systematic search of the PubMed, Ovid, EMBASE, and Cochrane databases. Data were searched using the following keywords: urinary tract cancer, urothelial carcinomas, renal pelvis, ureter, bladder cancer, chemotherapy, ureteroscopy, nephroureterectomy, neoplasm, (neo)adjuvant treatment, instillation, recurrence, risk factors, metastatic, immunotherapy, and survival. The results were assessed by a panel of experts. EVIDENCE SYNTHESIS: Even though data are accruing, for many areas there is still insufficient high-level evidence to provide strong recommendations. Patient stratification on the basis of histology and clinical examination (including imaging) and assessment of patients at risk of Lynch syndrome will aid management. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk UTUC and two functional kidneys. In particular, for patients with high-risk or metastatic UTUC, new treatment options have become available. In high-risk UTUC, platinum-based chemotherapy after radical nephroureterectomy, and adjuvant nivolumab for unfit or patients who decline chemotherapy, are options. For metastatic disease, gemcitabine/carboplatin chemotherapy is recommended as first-line treatment for cisplatin-ineligible patients. Patients with PD-1/PD-L1-positive tumours should be offered a checkpoint inhibitor (pembrolizumab or atezolizumab). CONCLUSIONS: These guidelines contain information on the management of individual patients according to the current best evidence. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen according to the risk stratification of these tumours. PATIENT SUMMARY: Cancer of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, timely and appropriate diagnosis is most important. A number of known risk factors exist.
Department of Pathology General Hospital of Vienna Medical University of Vienna Vienna Austria
Department of Pathology Sorbonne University AP HP Hôpital Tenon Paris
Department of Translational Medicine Lund University Malmö Sweden
Department of Urology Bichat Claude Bernard Hospital AP HP Université de Paris Paris France
Department of Urology Caritas St Josef Medical Center University of Regensburg Regensburg Germany
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology Edinburgh Bladder Cancer Surgery Western General Hospital Edinburgh UK
Department of Urology Fundación Instituto Valenciano de Oncología Valencia Spain
Department of Urology La Croix Du Sud Hospital Quint Fonsegrives France
Department of Urology Skåne University Hospital Malmö Sweden
Department of Urology The Stokes Centre for Urology Royal Surrey Hospital Guildford UK
Department of Urology Université de Paris AP HP Saint Louis Hospital Paris France
GRC 5 Predictive Onco Uro Sorbonne University AP HP Urology Pitie Salpetriere Hospital Paris France
Lancashire Teaching Hospitals NHS Foundation Trust Preston UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010942
- 003
- CZ-PrNML
- 005
- 20230801132717.0
- 007
- ta
- 008
- 230718s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2023.03.013 $2 doi
- 035 __
- $a (PubMed)36967359
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Rouprêt, Morgan $u GRC 5 Predictive Onco-Uro, Sorbonne University, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France. Electronic address: morgan.roupret@aphp.fr
- 245 10
- $a European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update / $c M. Rouprêt, T. Seisen, AJ. Birtle, O. Capoun, EM. Compérat, JL. Dominguez-Escrig, I. Gürses Andersson, F. Liedberg, P. Mariappan, A. Hugh Mostafid, B. Pradere, BWG. van Rhijn, SF. Shariat, BP. Rai, F. Soria, V. Soukup, RG. Wood, EN. Xylinas, A. Masson-Lecomte, P. Gontero
- 520 9_
- $a CONTEXT: The European Association of Urology (EAU) guidelines panel on upper urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in evidence-based management of UTUC. OBJECTIVE: To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. EVIDENCE ACQUISITION: The recommendations provided in these guidelines are based on a review of the literature via a systematic search of the PubMed, Ovid, EMBASE, and Cochrane databases. Data were searched using the following keywords: urinary tract cancer, urothelial carcinomas, renal pelvis, ureter, bladder cancer, chemotherapy, ureteroscopy, nephroureterectomy, neoplasm, (neo)adjuvant treatment, instillation, recurrence, risk factors, metastatic, immunotherapy, and survival. The results were assessed by a panel of experts. EVIDENCE SYNTHESIS: Even though data are accruing, for many areas there is still insufficient high-level evidence to provide strong recommendations. Patient stratification on the basis of histology and clinical examination (including imaging) and assessment of patients at risk of Lynch syndrome will aid management. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk UTUC and two functional kidneys. In particular, for patients with high-risk or metastatic UTUC, new treatment options have become available. In high-risk UTUC, platinum-based chemotherapy after radical nephroureterectomy, and adjuvant nivolumab for unfit or patients who decline chemotherapy, are options. For metastatic disease, gemcitabine/carboplatin chemotherapy is recommended as first-line treatment for cisplatin-ineligible patients. Patients with PD-1/PD-L1-positive tumours should be offered a checkpoint inhibitor (pembrolizumab or atezolizumab). CONCLUSIONS: These guidelines contain information on the management of individual patients according to the current best evidence. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen according to the risk stratification of these tumours. PATIENT SUMMARY: Cancer of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, timely and appropriate diagnosis is most important. A number of known risk factors exist.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z přechodných buněk $x diagnóza $x terapie $x patologie $7 D002295
- 650 12
- $a urologie $7 D014572
- 650 12
- $a nádory močového měchýře $x patologie $7 D001749
- 650 12
- $a nádory ledvin $x diagnóza $x terapie $x patologie $7 D007680
- 650 _2
- $a ledvinná pánvička $x patologie $7 D007682
- 650 12
- $a nádory močovodu $x diagnóza $x terapie $x patologie $7 D014516
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Seisen, Thomas $u GRC 5 Predictive Onco-Uro, Sorbonne University, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France
- 700 1_
- $a Birtle, Alison J $u Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK; University of Manchester, Manchester, UK
- 700 1_
- $a Capoun, Otakar $u Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia; Department of Pathology, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Compérat, Eva M $u Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia; Department of Pathology, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria; Department of Pathology, Sorbonne University, AP-HP, Hôpital Tenon, Paris
- 700 1_
- $a Dominguez-Escrig, José L $u Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain
- 700 1_
- $a Gürses Andersson, Irene $u Patient advocate, Bladder Cancer Norway, Norway
- 700 1_
- $a Liedberg, Fredrik $u Department of Translational Medicine, Lund University, Malmö, Sweden; Department of Urology, Skåne University Hospital, Malmö, Sweden
- 700 1_
- $a Mariappan, Paramananthan $u Department of Urology, Edinburgh Bladder Cancer Surgery, Western General Hospital, Edinburgh, UK
- 700 1_
- $a Hugh Mostafid, A $u Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France
- 700 1_
- $a van Rhijn, Bas W G $u Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czechia; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria
- 700 1_
- $a Rai, Bhavan P $u Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- 700 1_
- $a Soria, Francesco $u Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
- 700 1_
- $a Soukup, Viktor $u Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia; Department of Pathology, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Wood, Robbert G $u Patient advocate, Bladder Cancer Norway, Norway
- 700 1_
- $a Xylinas, Evanguelos N $u Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Université de Paris, Paris, France
- 700 1_
- $a Masson-Lecomte, Alexandra $u Department of Urology, Université de Paris, AP-HP, Saint Louis Hospital, Paris, France
- 700 1_
- $a Gontero, Paolo $u Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 84, č. 1 (2023), s. 49-64
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36967359 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132714 $b ABA008
- 999 __
- $a ok $b bmc $g 1963390 $s 1197207
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 84 $c 1 $d 49-64 $e 20230324 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20230718
